Avalon GloboCare (ALBT) – What Does the Company Do? Stock Outlook, Earnings, Market Cap, Related Stocks, and Headquarters at a Glance
ALBT is a U.S. micro-cap Nasdaq-listed healthcare holding company that combines the breath-diagnostic device KetoAir, CAR-T and CAR-NK cell-therapy assets, and a clinical operations (MSO) business.
Subscribe🏢 What kind of company is Avalon GloboCare?
ALBT (Avalon GloboCare Corp.) is a U.S. Nasdaq-listed healthcare holding company that operates a multi-segment business model spanning precision-diagnostic consumer products, cell-therapy intellectual property, and clinical-trial operations (MSO). At one point the company held real estate assets as its core revenue source, but its business portfolio has since been reshaped around healthcare and diagnostics.
It has two core asset pillars. The first is its lineup of precision-diagnostic consumer devices, including the KetoAir™ breathalyzer, which measures breath ketones, ammonia, and biomarkers. The second is its clinical-stage CAR-T and CAR-NK cell-therapy pipeline. It also runs a smaller AI content and publishing business as an adjacent segment.
💰 How does it make money?
| Business Segment | Revenue Mix | Description |
|---|---|---|
| Lab Services MSO | Majority | Revenue from clinical-trial operations and management subsidiary; the largest segment of total sales |
| AI Publishing & Other | Supportive | AI-based content and publishing revenue and other ancillary businesses |
Latest annual revenue stands at $1.1M, with sales growth of -21.2%, reflecting the ongoing business-model transition. Because quarterly revenue is extremely small, the company's value is driven less by sales and more by clinical progress, the pace of KetoAir commercialization, and its cash runway. Operating losses have persisted.
📐 Market cap and corporate scale
Market capitalization stands at $4.0M, roughly About 0% the size of Samsung Electronics's market cap. The company has 2 people employees.
ALBT's market cap of $4.0M places it firmly in the micro-cap tier of the healthcare sector. The company has around 2 people employees, with an operating margin of -733.1% and a return on equity (ROE) of -214.5%, both reflecting a loss-making structure typical of early-stage clinical and commercialization phases.
📈 Avalon GloboCare outlook and share-price trends
1-Year Price Performance
Analyst Consensus
52-Week Price RangeALBT's business outlook hinges on the speed of commercialization for its precision-diagnostic consumer devices and the progress of its clinical-stage cell-therapy pipeline. Breath diagnostics built around KetoAir are being expanded beyond ketone and metabolic monitoring through joint development with subsidiary Qi Diagnostics, targeting new applications such as real-time cannabis breath-detection (analogous to DUI enforcement models).
Earnings per share (EPS) come in at $-8.25, while the debt-to-equity ratio stands at 0.12, meaning the loss-making structure continues and additional capital raises are repeatedly required. The CAR-T and CAR-NK assets offer option value through potential licensing or partnership deals, but their near-term revenue contribution remains limited.
⚔️ Key competitive strengths and risks
ALBT is a diversified healthcare holding company that combines precision-diagnostic consumer devices with cell-therapy intellectual property, carrying both the upside of a business-model transition and the burden of a loss-making structure.
💪 Key Competitive Strengths
⚠️ Key Risks
🔄 Competitors and related (beneficiary) stocks
Broad competitors in the breath-diagnostics and health-device space include DXCM (DexCom), ABT (Abbott Laboratories), TMO (Thermo Fisher Scientific), and HOLX (Hologic), while in clinical operations (MSO) the business overlaps partly with large CROs such as IQV (IQVIA) and ICLR (ICON).
Related stocks include GILD (Gilead Sciences, owner of Kite) and BMY (Bristol Myers Squibb, owner of Juno) in the CAR-T and CAR-NK cell-therapy space, along with LEGN (Legend Biotech), and MDT (Medtronic) as a comparison point on the breath-diagnostics side.
Competitors| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
| DXCM | Dexcom Inc | $84.53 | -3.8% | $31.9B | 33.4 | 12.2 | 38.49% | - |
| ABT | Abbott Laboratories | $105.52 | -2.6% | $182.6B | 34.1 | 3.6 | 10.63% | 2.44% |
| TMO | Thermo Fisher Scientific Inc | $603.02 | -1.8% | $223.0B | 32.4 | 4.2 | 13.51% | 0.31% |
| IQV | IQVIA Holdings Inc | $259.21 | -3.2% | $42.7B | 32.1 | 6.9 | 23.01% | - |
 ICLR | Icon Plc | $158.34 | -4.0% | $12.2B | 287.4 | 1.3 | 0.45% | - |
Related stocks (beneficiaries)| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
| GILD | Gilead Sciences Inc | $146.64 | -2.9% | $181.8B | - | 15.4 | -20.57% | 2.22% |
| BMY | Bristol-Myers Squibb Co | $64.69 | -3.2% | $132.1B | 14.3 | 5.9 | 46.7% | 3.61% |
 LEGN | Legend Biotech Corp ADR | $20.49 | -4.8% | $4.0B | - | 3.2 | -8.11% | - |
✅ Investor checkpoints
ALBT is a micro-cap healthcare holding company in which business diversification and ongoing losses are progressing simultaneously. Investors should track progress by business line and cash balance together rather than focusing on top-line revenue alone.
| Checkpoint | What to verify | Current status |
|---|---|---|
| 🧪 KetoAir commercialization progress | Monitor KetoAir device sales, regulatory expansion, and progress on new applications (e.g., cannabis breath testing). | Check quarterly reports and press releases |
| 🧬 CAR-T clinical progress | Track clinical data and pre-IND/FDA meeting outcomes for CAR-T candidates such as AVA-001 and AVA-011. | Check filings and clinical updates |
| 🏥 MSO revenue flow | Verify that the clinical-operations (MSO) subsidiary continues to contribute stable quarterly revenue. | Check segment revenue in 10-Q |
| 💼 Capital-raising activity | Track capital-raising disclosures such as ATM offerings, private placements, and convertible notes, along with changes in shares outstanding. | Check 8-K and 10-Q filings |
Persistent operating losses and repeated capital raises amplify the share-dilution burden, while business diversification raises the risk of management-efficiency drag from scattered resources. In addition, the micro-cap profile means that the risk of failing to meet Nasdaq listing-maintenance requirements can amplify short-term volatility.
ALBT is a diversified healthcare holding company operating precision diagnostics, cell therapy, and clinical operations under a single roof. For this stock, a multi-dimensional view that tracks the achievement of each business's milestones alongside the cash balance—rather than near-term revenue—is essential.
On US Stock Today's real-time dashboard, check Avalon GloboCare's live quotes, technical indicators, and peer comparisons at a glance.
Subscribe Today's 5 AI picks, all free